Sign in or Register   Sign in or Register
  |  

Mouse Anti-F9 Recombinant Antibody (CBXF-2536) (CBMAB-F2708-CQ)

This product is a mouse antibody that recognizes F9. The antibody CBXF-2536 can be used for immunoassay techniques such as: ELISA, IHC, RIA, WB.
See all F9 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBXF-2536
Antibody Isotype
IgG1
Application
ELISA, IHC, RIA, WB

Basic Information

Immunogen
Human factor IX
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
50% glycerol, ddH2O
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Coagulation Factor IX
Introduction
This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing.
Entrez Gene ID
UniProt ID
Alternative Names
Coagulation Factor IX; Plasma Thromboplastic Component; Plasma Thromboplastin Component; Christmas Factor; EC 3.4.21.22; PTC; Christmas Disease; Hemophilia B; Factor IX F9;
Research Area
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Biological Process
Blood coagulation Source: UniProtKB
Proteolysis Source: UniProtKB
Zymogen activation Source: UniProtKB
Cellular Location
Secreted
Involvement in disease
Hemophilia B (HEMB):
An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Mutations in position 43 (Oxford-3, San Dimas) and 46 (Cambridge) prevents cleavage of the propeptide (PubMed:12588353, PubMed:2738071, PubMed:3009023, PubMed:8295821, PubMed:9169594, PubMed:9600455, PubMed:25251685). Mutation in position 93 (Alabama) probably fails to bind to cell membranes (PubMed:3790720). Mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya or Hilo) prevent cleavage of the activation peptide (PubMed:6603618, PubMed:8076946, PubMed:12588353, PubMed:2162822, PubMed:25251685, PubMed:2713493).
Thrombophilia, X-linked, due to factor IX defect (THPH8):
A hemostatic disorder characterized by a tendency to thrombosis.
Warfarin sensitivity, X-linked (WARFS):
A condition characterized by sensitivity to warfarin, a drugs used as anti-coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. Warfarin sensitive individuals develop bleeding complications when they are given warfarin within the therapeutic ranges.
PTM
Activated by factor XIa, which excises the activation peptide (PubMed:9169594, PubMed:1730085). The propeptide can also be removed by snake venom protease (PubMed:20004170, PubMed:20080729).
The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.

Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan-Castillo, B., Fafián-Labora, J. A., Mitchell, T. P., ... & O’Loghlen, A. (2022). Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence. Cell death & disease, 13(2), 1-13.

Branchini, A., Morfini, M., Lunghi, B., Belvini, D., Radossi, P., Bury, L., ... & Svahn, J. (2022). F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 20(1), 69-81.

Kihlberg, K., Baghaei, F., Bruzelius, M., Funding, E., Holme, P. A., Lassila, R., ... & Astermark, J. (2022). Factor IX antibodies and tolerance in hemophilia B in the Nordic countries–The impact of F9 variants and complications. Thrombosis Research, 217, 22-32.

Yin, R., & Liu, C. (2022). Human coagulation factor IX: a systematic review of its characteristics. Blood Coagulation & Fibrinolysis, 33(1), 1-7.

Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Fafián-Labora, J. A., Mitchell, T. P., Nightingale, T. D., ... & O’Loghlen, A. (2021). The coagulation factor IX (F9) loss of function prevents the cell cycle arrest induced by CDK4/6 inhibitors treatment. bioRxiv.

Iyer, N., Al Qaryoute, A., Kacham, M., & Jagadeeswaran, P. (2021). Identification of zebrafish ortholog for human coagulation factor IX and its age‐dependent expression. Journal of Thrombosis and Haemostasis, 19(9), 2137-2150.

Sidonio, R. F., & Malec, L. (2021). Hemophilia B (Factor IX Deficiency). Hematology/Oncology Clinics, 35(6), 1143-1155.

Mohammed, B. M., Cheng, Q., Matafonov, A., Monroe, D. M., Meijers, J. C., & Gailani, D. (2018). Factor XI promotes hemostasis in factor IX‐deficient mice. Journal of Thrombosis and Haemostasis, 16(10), 2044-2049.

Ferrarese, M., Testa, M. F., Balestra, D., Bernardi, F., Pinotti, M., & Branchini, A. (2018). Secretion of wild‐type factor IX upon readthrough over F9 pre‐peptide nonsense mutations causing hemophilia B. Human Mutation, 39(5), 702-708.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-F9 Recombinant Antibody (CBXF-2536)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare